USD10
KNSA Ações
Sobre Kiniksa PharmaceuticalsKiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
USD10
KNSA Ações
Sobre Kiniksa PharmaceuticalsKiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Estatísticas
JANELA DE NEGOCIAÇÃO
Fechado
ABRE ÀS
Sem dados suficientes
CAPITALIZAÇÃO DE MERCADO
US$ 3,50 bi
PREÇO ABERTO
US$ 46,60
BAIXO (1 A)
US$ 18,26
ALTO (1 A)
US$ 49,12
BAIXO (24H)
US$ 45,44
ALTO (24H)
US$ 46,91
VOLUME (24H)
US$ 974,27 mil
140,27%
Histórico de preços
Time | Price | Change |
|---|---|---|
Hoje | US$ 46,60 | |
1 dia | US$ 46,76 | |
1 semana | US$ 45,99 | |
1 mês | US$ 44,29 | |
1 ano | US$ 22,21 |